RxDoctor Payments Data

Daniel Montalvo, MD

Internal Medicine · South Holland, ILNPI 1437165594

Payments from drug & device makers

$495in general payments, 2019–2025

Across 27 payments — averaging $18.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$127
  • Novartis$89
  • GSK$71
  • Bayer$54
  • Lilly USA, LLC$45
  • AstraZeneca$38
  • plus $72 from 3 others

What the payments were for

  • Food & beverage$495100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk7$127
Novartis6$89
GSK4$71
Bayer3$54
Lilly USA, LLC2$45
AstraZeneca2$38
Dexcom, Inc.1$31
Exact Sciences1$27
Amgen1$14

How this compares

$495 in reported general payments places this provider in the 65th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$86,480
Medicare patients
193
Services billed
1,077

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban163$156,586
JardianceEmpagliflozin81$99,627
Trelegy ElliptaFluticasone/Umeclidin/Vilanter116$90,007
JanuviaSitagliptin Phosphate62$65,253
OzempicSemaglutide54$63,779
XareltoRivaroxaban48$63,183
TradjentaLinagliptin19$29,022
EntrestoSacubitril/Valsartan21$25,838
WegovySemaglutide13$17,553
Albuterol Sulfate HfaAlbuterol Sulfate219$9,957
Breo ElliptaFluticasone/Vilanterol16$8,917
Lidocaine70$8,706
Lantus SolostarInsulin Glargine,hum.Rec.Anlog53$8,354
Atorvastatin Calcium868$6,869
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$6,787

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$71$98,924132 claims
Novo NordiskOzempic, Wegovy$127$81,33267 claims
NovartisEntresto$89$25,83821 claims
AstraZenecaSymbicort$38$6,15014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in South Holland

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →